Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    A091102
Show Display Options
Rank Status Study
1 Suspended Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Conditions: Myxofibrosarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Leiomyosarcoma;   Recurrent Liposarcoma;   Recurrent Malignant Peripheral Nerve Sheath Tumor;   Recurrent Undifferentiated Pleomorphic Sarcoma;   Stage III Soft Tissue Sarcoma;   Stage IV Soft Tissue Sarcoma
Interventions: Drug: Alisertib;   Other: Laboratory Biomarker Analysis

Study has passed its completion date and status has not been verified in more than two years.